LIBRELEASE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIBRELEASE (LIBRELEASE).

How it works

LIBRELEASE is a novel therapeutic agent that modulates neurotransmitter release by binding to presynaptic voltage-gated calcium channels, specifically the alpha-2-delta subunit, thereby reducing calcium influx and subsequent neurotransmitter exocytosis. This results in decreased neuronal excitability and modulation of pain pathways.

What the body does with it

Metabolism	LIBRELEASE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9. It undergoes reduction and subsequent glucuronidation to inactive metabolites that are excreted renally.
Excretion	Primarily renal excretion of unchanged drug (60–70%) and hepatic metabolism with biliary/fecal elimination (20–30%).
Half-life	Terminal elimination half-life 12–15 hours in healthy adults; prolonged in renal impairment (up to 30 hours).
Protein binding	95% bound to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.3–0.5 L/kg, indicating distribution into total body water with moderate tissue binding.
Bioavailability	Oral: 80–90% due to first-pass metabolism; negligible absorption via topical route.
Onset of Action	Oral: 30–60 minutes; intravenous: 2–5 minutes.
Duration of Action	Oral: 8–12 hours; intravenous: 4–6 hours, dose-dependent.

Classification & Brands

Dosing & administration

10 mg once daily, oral, administered in the morning.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	GFR 30-59 mL/min: 5 mg once daily; GFR 15-29 mL/min: 2.5 mg once daily; GFR <15 mL/min: not recommended.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: 5 mg once daily; Child-Pugh Class C: not recommended.
Pediatric use	Weight-based: 0.1 mg/kg once daily, oral, maximum 10 mg daily; not approved for children <6 years.
Geriatric use	Age >65 years: starting dose 5 mg once daily, titrate cautiously; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIBRELEASE (LIBRELEASE).

Breastfeeding	LIBRELEASE is excreted into human breast milk with a milk-to-plasma ratio (M/P) of 1.2. Due to the risk of severe adverse effects in the nursing infant (e.g., nephrotoxicity, hepatotoxicity), breastfeeding is contraindicated during therapy and for 7 days after the last dose.
Teratogenic Risk	LIBRELEASE is classified as FDA Pregnancy Category X. First trimester: High risk of major malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second trimester: Continued risk of structural defects and potential for intrauterine growth restriction (IUGR). Third trimester: Risk of fetal toxicity, including oligohydramnios and neonatal nephrotoxicity.

Warnings & precautions

■ FDA Black Box Warning

LIBRELEASE is associated with an increased risk of suicidal thoughts and behavior in patients taking this drug for any indication. Monitor closely for emerging or worsening depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to LIBRELEASE or any of its components. Concurrent use with MAO inhibitors or within 14 days of discontinuation. Severe renal impairment (CrCl <30 mL/min) without dose adjustment. History of drug-induced pancreatitis.

Clinical Precautions

Precautions

Angioedema: Can occur with first dose or at any time. Discontinue immediately if symptoms develop. Hypersensitivity reactions: Including urticaria, pruritus, and anaphylaxis. Suicidal ideation: As per black box warning. Dizziness and somnolence: May impair ability to drive or operate machinery. Renal impairment: Dose adjustment required for CrCl <60 mL/min. Hepatic impairment: Use with caution; reduced doses recommended. Pancreatitis: Discontinue if symptoms develop.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LIBRELEASE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIBRELEASE (LIBRELEASE).

How it works

What the body does with it

Metabolism	LIBRELEASE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9. It undergoes reduction and subsequent glucuronidation to inactive metabolites that are excreted renally.
Excretion	Primarily renal excretion of unchanged drug (60–70%) and hepatic metabolism with biliary/fecal elimination (20–30%).
Half-life	Terminal elimination half-life 12–15 hours in healthy adults; prolonged in renal impairment (up to 30 hours).
Protein binding	95% bound to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.3–0.5 L/kg, indicating distribution into total body water with moderate tissue binding.
Bioavailability	Oral: 80–90% due to first-pass metabolism; negligible absorption via topical route.
Onset of Action	Oral: 30–60 minutes; intravenous: 2–5 minutes.
Duration of Action	Oral: 8–12 hours; intravenous: 4–6 hours, dose-dependent.

Classification & Brands

Dosing & administration

10 mg once daily, oral, administered in the morning.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	GFR 30-59 mL/min: 5 mg once daily; GFR 15-29 mL/min: 2.5 mg once daily; GFR <15 mL/min: not recommended.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: 5 mg once daily; Child-Pugh Class C: not recommended.
Pediatric use	Weight-based: 0.1 mg/kg once daily, oral, maximum 10 mg daily; not approved for children <6 years.
Geriatric use	Age >65 years: starting dose 5 mg once daily, titrate cautiously; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIBRELEASE (LIBRELEASE).

Breastfeeding	LIBRELEASE is excreted into human breast milk with a milk-to-plasma ratio (M/P) of 1.2. Due to the risk of severe adverse effects in the nursing infant (e.g., nephrotoxicity, hepatotoxicity), breastfeeding is contraindicated during therapy and for 7 days after the last dose.
Teratogenic Risk	LIBRELEASE is classified as FDA Pregnancy Category X. First trimester: High risk of major malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second trimester: Continued risk of structural defects and potential for intrauterine growth restriction (IUGR). Third trimester: Risk of fetal toxicity, including oligohydramnios and neonatal nephrotoxicity.